The molecular glue space has attracted several Big Pharma players over the past few years, including Novo Nordisk, Pfizer and ...

The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies ...

Eisai’s cuts will affect 121 employees across the Japanese company’s U.S. operations, including 57 people at its American ...

In the five weeks since Donald Trump returned as U.S. president, the FDA, NIH and CDC have been thrown into disarray, with ...

In a move straight out of 2021, BridgeBio Oncology is taking the SPAC route to the public markets in a deal with Helix ...

The licensing deal follows years of controversy for Cassava, as well as the high-profile late-stage failure of its ...

The search for a partner for zerlasiran is ongoing, according to Silence. In the meantime, the biotech will focus its ...

ITF, IntraBio and Orchard are among the companies that have won FDA nods in the past year for Duchenne muscular dystrophy, ...

The back-to-back high-level disruptions in vaccine policy under Robert F. Kennedy Jr. comes as the U.S. records its first ...

As it did during the COVID-19 pandemic, mRNA technology offers an efficient way forward in developing products for diseases ...

The move comes after President Donald Trump warned Big Pharma leaders that he would impose tariffs on them if they refuse to ...

While Kallyope’s drugs are mechanistically unique, the biotech is competing in a crowded space, with other therapies that ...